ArticleMedicine2026
Effect of prophylactic HPV vaccination and timing of administration on recurrence of cervical HSIL after LEEP: A retrospective study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The objective of this study was to identify risk factors for recurrent cervical high-grade squamous intraepithelial lesions (HSIL/CIN2-3) following loop electrosurgical excision procedure (LEEP), with a particular focus on evaluating the protective effect of human papillomavirus (HPV) vaccination, including effective timing of administration, against disease recurrence. This retrospective study analyzed 343 patients with colposcopy-directed biopsy-confirmed cervical HSIL who underwent LEEP, including 127 vaccinated and 216 unvaccinated individuals. Multivariate logistic regression analysis was employed to identify risk factors associated with HSIL recurrence. Receiver operating characteristic (ROC) curve analysis was used to determine the optimal cutoff timing of HPV vaccination for preventing post-LEEP HSIL recurrence. Among the 343 patients, the post-LEEP HSIL recurrence rate was 9.0%. Multivariate logistic analysis identified CIN3 (OR = 2.956, 95% CI 1.046-8.352, P = .041), glandular involvement (OR = 3.517, 95% CI 1.165-10.621, P = .026), positive margins (OR = 2.496, 95% CI 1.100-5.667, P = .029), and persistent HPV infection (OR = 6.253, 95% CI 2.043-19.135, P = .001) as independent risk factors for HSIL recurrence. HPV vaccination was associated with a lower risk of HSIL recurrence (OR = 0.249, 95% CI 0.082-0.760, P = .015). ROC analysis indicated that administration of the HPV vaccine within 6 months post-LEEP was the optimal cutoff time for preventing recurrence (AUC = 0.851, P = .017). Vaccination either before LEEP or within this 6-month postoperative period significantly reduced the risk of HSIL recurrence (P = .034). CIN3, gland involvement, positive margins, and persistent HPV infection increase the risk of cervical HSIL recurrence after LEEP. HPV vaccination, when administered either before or within 6 months after LEEP, is associated with a lower risk of cervical HSIL recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.